Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pEXO-001, also known as pExo, is a human placenta-derived exosome product developed by Celularity, Inc. It is currently in preclinical development, primarily for the treatment of osteoarthritis (OA), specifically knee osteoarthritis (KOA). pEXO-001 consists of extracellular vesicles secreted from human postpartum placentas, containing a diverse array of cellular components such as proteins, microRNAs, lipids, cytokines, and chemokines. Its proposed mechanism of action involves delivering pro-regenerative factors, promoting chondrocyte migration and proliferation, suppressing inflammation and catabolism, and activating cell growth signaling pathways. These actions contribute to alleviating pain and restoring cartilage damage in OA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pEXO-001.